- Home
- RYN vs TVTX Comparison
RYN vs TVTX Comparison
Compare RYN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | TVTX |
|---|---|---|
| Founded | 1926 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RYN | TVTX |
|---|---|---|
| Price | $22.01 | $34.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $27.25 | ★ $37.21 |
| AVG Volume (30 Days) | 1.4M | ★ 1.4M |
| Earning Date | 02-04-2026 | 10-30-2025 |
| Dividend Yield | ★ 13.23% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $1,293,371,000.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.36 |
| Revenue Next Year | N/A | $37.33 |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | 60.70 | ★ 114.22 |
| 52 Week Low | $21.06 | $12.91 |
| 52 Week High | $29.38 | $37.50 |
Technical Indicators
Market Signals| Indicator | RYN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 54.14 |
| Support Level | $21.59 | $33.84 |
| Resistance Level | $22.85 | $35.97 |
| Average True Range (ATR) | 0.53 | 1.45 |
| MACD | 0.14 | -0.33 |
| Stochastic Oscillator | 46.55 | 30.86 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.